Artelo Biosciences Expands into Glaucoma Market

Artelo Biosciences is strategically expanding its presence into the $16.3 billion glaucoma market with a fully funded study. This move underscores the strength and versatility of its multi-platform pipeline. The company's approach, centered on three clinical programs and a core molecule, emphasizes capital efficiency. This expansion into a significant therapeutic area demonstrates Artelo's commitment to sustained growth beyond its current indications and leverages its research and development capabilities for broader market penetration.